Favorable Survival Time Provided with Radioembolization in Hepatocellular Carcinoma Patients with and Without Portal Vein Thrombosis

Ozkan Z. G., Poyanli A., Ucar A., Kuyumcu S., Akyuz F., Keskin S., ...Daha Fazla

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, cilt.30, sa.3, ss.132-138, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1089/cbr.2014.1748
  • Dergi Adı: CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.132-138
  • Anahtar Kelimeler: selective intraarterial radionuclide therapy, Y-90 microspheres, radioembolization, SIRT, portal vein thrombosis, hepatocellular carcinoma, Y-90 MICROSPHERES, LIVER-DISEASE, PROGNOSTIC-FACTORS, EXPERIENCE, SORAFENIB, SAFETY
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose: Although some algorithms are defined for the treatment of advanced hepatocellular carcinoma (HCC), the expected survival cannot be prolonged as it is intended. Treatment options for this group of patients are limited. Radioembolization with yttrium-90 (Y-90) microspheres is a new treatment modality, which has also been used in advanced HCC patients. In this study, the authors aimed to assess the efficiency of radioembolization with Y-90 microspheres and evaluate prognostic factors that influence the survival in HCC patients.